Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.55 |
| ▸ | TK2 | O00142 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838333 | 0.86 | TK1 (0.56) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL28119693 | 0.85 | TYMS (0.51) | — | |
| SCHEMBL16741005 | 0.84 | DNMT1 (0.55) | LMNASMN1; SMN2 | |
| SCHEMBL28803677 | 0.83 | TK1 (0.52) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL16546364 | 0.83 | TK1 (0.52) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL16741002 | 0.82 | DNMT1 (0.44) | TK1TK2 | |
| SCHEMBL28273261 | 0.80 | TK2 (0.45) | TK2 | |
| SCHEMBL16373946 | 0.79 | TK1 (0.52) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL19876156 | 0.79 | TK1 (0.52) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL22015702 | 0.79 | TK1 (0.52) | TK1TK2LMNASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112961860-A | Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated disorders | 私募蛋白质体公司 | 2021-06-15 | — | — | CN | claimed |
| CN-110643610-A | Nucleic acid compounds for binding complement component 3 proteins | 私募蛋白质体公司 | 2020-01-03 | — | — | CN | claimed |
| EP-3335714-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | Quest Diagnostics Investments Incorporated (US) | 2018-06-20 | — | — | EP | claimed |
| US-20170328909-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-11-16 | — | — | US | claimed |
| US-9651556-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-05-16 | — | — | US | claimed |
| EP-2451981-B1 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC INC (US) | 2016-10-19 | — | — | EP | claimed |
| US-9382533-B2 | Method for generating aptamers with improved off-rates | SOMALOGIC, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-9316647-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | SOMALOGIC, INC. (US) | 2016-04-19 | — | — | US | claimed |
| US-20150148237-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC OPERATING CO. INC. | 2015-05-28 | — | — | US | claimed |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024118776-A1 | MATERIALS AND METHODS FOR APTAMER SELECTION | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-109439664-B | Aptamer binding to IL-6 and use thereof in the treatment or diagnosis of IL-6 mediated disorders | 私募蛋白质体操作有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4323524-A1 | NUCLEIC ACID COMPOUNDS THAT BIND CORONAVIRUS PROTEINS | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4323374-A1 | MODIFIED NUCLEOSIDES | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20120115752-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7964356-B2 | Method for generating aptamers with improved off-rates | SOMALOGIC, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7947447-B2 | Method for generating aptamers with improved off-rates | SOMALOGIC, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110082286-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011006075-A1 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082286-A1 | Method for Generating Aptamers with Improved Off-Rates | DDX1, DDX3X, DDX18 | TK1 214/4885TK2 864/4885LMNA 753/4885 |
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | DDX1, DDX3X, DDX18 | TK1 214/4885TK2 864/4885LMNA 753/4885 |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SARS1, RNGTT, PABPC1 | TK1 1812/4885TK2 3270/4885LMNA 1529/4885 |
| US-20170328909-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | EGFR, ERBB2, ERBB3 | TK1 187/4885TK2 598/4885LMNA 2108/4885 |
| US-20120115752-A1 | Method for Generating Aptamers with Improved Off-Rates | CD2BP2, ENTPD8, ENTPD1 | TK1 55/4885TK2 251/4885LMNA 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.